Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts

Hypertension Research

Volumn 30, Issue 5, 2007, Pages 427-437

  Takeda, Mitsuo ^a   Tatsumi, Tetsuya ^a   Matsunaga, Shinsaku ^a   Hayashi, Hironori ^a   Kimata, Masaki ^a   Honsho, Shoken ^a   Nishikawa, Susumu ^a   Mano, Akiko ^a   Shiraishi, Jun ^a   Yamada, Hiroyuki ^a   Takahashi, Tomosaburo ^a   Matoba, Satoaki ^a   Kobara, Miyuki ^b   Matsubara, Hiroaki ^a  

^a KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Apoptosis; Heart failure; Myocardial infarction; Remodeling

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEMODYNAMICS; INTERMETHOD COMPARISON; LEFT CORONARY ARTERY; MALE; MUSCLE CELL; NICK END LABELING; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; STAINING; SURVIVAL RATE; UPREGULATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ALDOSTERONE ANTAGONISTS; ANIMALS; APOPTOSIS; BLOOD PRESSURE; CELLS, CULTURED; FIBROSIS; GENE EXPRESSION REGULATION; HEART RATE; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SPIRONOLACTONE; SURVIVAL RATE; VENTRICULAR REMODELING;

EID: 34250742595     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.427     Document Type: Article

References (53)

1. Pfeffer MA: Left ventricular remodeling after acute myocardial infarction. Annu Rev Med 1995; 46: 455-466.
2. Tatsumi T, Shiraishi J, Keira N, et al: Intracellular ATP is required for mitochondrial apoptotic pathways in isolated hypoxic rat cardiac myocytes. Cardiovasc Res 2003; 52: 428-440.
3. Fliss H, Gattinger D: Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996; 79: 949-956.
4. Kajstura J, Cheng W, Reiss K, et al: Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996; 74: 86-107.
5. Cheng W, Kajstura J, Nitahara JA, et al: Programmed myocyte cell death affects the viable myocardium after infarction in rats. Exp Cell Res 1996; 226: 316-327.
6. Olivetti G, Quaini F, Sala R, et al: Acute myocardial infarction in humans is associated with the activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 1996; 28: 2005-2016.
7. Beltrami CA, Finato N, Rocco M, et al: Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994; 89: 151-163.
8. Olivetti G, Abbi R, Quaini F, et al: Apoptosis in the failing human heart. N Eng J Med 1997; 336: 1131-1141.
9. Saraste A, Pulkki K, Kallajoki M, et al: Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest 1999; 29: 380-386.
10. Packer M: The neurohormoAal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-254.
11. Sato A, Saruta T: AldosteronP-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303-310.
12. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
13. Pitt B, Remme W, Zannad F, et al, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
14. Mizuno Y, Yoshimura M, Yasue H, et al: Aldosterone production is activated in the failing ventricles in human. Circulation 2001; 103: 72-77.
15. Yamamoto N, Yasue H, Mizuno Y, et al: Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002; 39: 958-962.
16. Silvestre JS, Robert V, Heymes C, et al: Myocardial production of aldosterone and corticosterone in the rat: Physiological regulation. J Biol Chem 1998; 273: 4883-4891.
17. Struthers AD, MacDonald TM: Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-670.
18. Funder JW: Glucocorticoid and mineralocortBcoid receptors: biology and clinical relevance. Annu Rev Med 1997; 48: 231-240.
19. +-dependent 11β-hydroxysteroid dehydrogenase in the human heart. J Mol Cell Cardiol 1996; 28: 781-787.
20. Mano A, Tatsumi T, Shiraishi J, et al: Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation 2004; 110: 317-323.
21. Kobara M, Tatsumi T, Kambayashi D, et al: Effect of ACE inhibition on myocardial apoptosis in an ischemia-reperfusion rat heart model. J Cardiovasc Pharmacol 2003; 41: 880-889.
22. Veliotes DGA, Woodiwiss AJ, Deftereos DAJ, Gray D, Osadchii O, Norton GR: Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by β-adrenoreceptor activation. Hypertension 2005; 45: 914-920.
23. Bäcklund T, Palojoki E, Saraste A, et al: Effect of vasopeptide inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction. Cardiovasc Res 2003; 57: 727-737.
24. Delyani JA, Robinson EL, Rudolph AE: Effect of a selecfive aldosterone receptor antagonist in myocardial infarction. Am J Physiol 2001; 50: H647-H654.
25. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-1364.
26. Roussoulieres AL, Raisky O, Chalabreysse L, et al: Identification and characterization of two genes (MIP-1β, VECADHERIN) implicated in acute rejection in human heart transplantation: Use of murine models in tandem with cDNA arrays. Circulation 2005; 111: 2636-2644.
27. Delcayre C, Swynghedauw B: Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 2002; 34: 1577-1584.
28. Solomon SD, Pfeffer MA: Aldosterone antagonism and myocardial infarction. From animals to man and back. J Am Coll Cardiol 2003; 42: 1674-1676.
29. Zannad F, Alla F, Dousset B, Perez A, Pitt B, RALES Investigators: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000; 102: 2700-2706.
30. Suzuki G, Morita H, Mishima T, et al: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002; 106: 2967-2972.
31. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003; 42: 1666-1673.
32. Hayakawa K, Takemura G, Kanoh M, et al: Inhibition of granulation tissue cell apoptosis during the subacute stage of myocardial infarction improves cardiac remodeling and dysfunction at the chronic stage. Circulation 2003; 108: 104-109.
33. Wencker D, Chandra M, Nguyen K, et al: A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003; 111: 1497-1504.
34. Foo RSY, Mani K, Kitsis RN: Death begets failure in the heart. J Clin Invest 2005; 115: 565-571.
35. Cesselli D, Jakoniuk I, Barlucchi L, et al: Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001; 89: 279-286.
36. Chandrashekhar Y, Sen S, Anway R, Shuros A, Anand I: Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J Am Coll Cardiol 2004; 43 295-301.
37. Leri A, Claudio PP, Li Q, et al: Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 1998; 101: 1326-1342.
38. de Gasparo M, Joss U, Ramjoue HP, et al: Three new epoxy-spironolactone derivatives: Characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650-656.
39. Silvestre JS, Heymes C, Oubenaissa A, et al: Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-2701.
40. Katada J, Meguro T, Saito H, et al: Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knock-out mice after myocardial infarction. Circulation 2005; 111: 2157-2164.
41. Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 986-989.
42. Sheppard KE, Autelitano DJ: 11β-Hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology 2002; 143 198-204.
43. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71: 503-510.
44. Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583.
45. Sato A, Funder JW: High glucose stimulates aldosterone-induced hypertrophy via type 1 meneralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996; 137: 4145-4153.
46. Qin W, Rudolph AE, Bond BR, et al: Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003; 93: 69-76.
47. Nagata K, Obata K, Xu J, et al: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656-664.
48. Konishi A, Tazawa C, Miki Y, et al: The possible roles of mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hypertensive rat. J Steroid Biochem Mol Biol 2003; 85: 439-442.
49. Castren M, Trapp T, Berninger B, Castren E, Holsboer F: Transcriptional induction of rat mineralocorticoid receptor gene in neurones by corticosteroids. J Mol Endocrinol 1995; 14: 285-293.
50. Lister K, Autelitano DJ, Jenkins A, Hannan RD, Sheppard KE: Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: A possible role for SGK1. Cardiovasc Res 2006; 70: 555-565.
51. Sun K, Yang K, Challis JR: Differential regulation of 11β-hydroxysteroid dehydrogenase type 1 and 2 by nitric oxide in cultured human placental trophoblast and chorionic cell preparation. Endocrinology 1997; 138: 4912-4920.
52. Suzuki S, Tsubochi H, Ishibashi H, et al: Inflammatory mediators down-regulate 11β-hydroxysteroid dehydrogenase type 2 in a human lung epithelial cell line BEAS-2B and the rat lung. Tohoku J Exp Med 2005; 207: 293-301.
53. Fukushima K, Funayama Y, Yonezawa H, et al: Aldosterone enhances 11β-hydroxysteroid dehydrogenase type 2 expression in colonic epithelial cells in vivo. Scand J Gastroenterol 2005; 40: 850-857.